Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...
Despite recent gains, analysts remain divided. Firms like Mizuho and Royal Bank of Canada have adopted more cautious tones, even as others, such as Bank of America, have raised their price targets to ...
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...
On Friday, Wedbush Securities sustained its optimistic stance on Tesla (NASDAQ:TSLA), maintaining an Outperform rating and a $400.00 price target for the electric vehicle and clean energy company.
On Friday, Wedbush Securities sustained its optimistic stance on Tesla (NASDAQ:TSLA), maintaining an Outperform rating and a $400.00 price target for the electric vehicle and clean energy company.